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Abstract: Toll-like receptor (TLR) agonists represent potentially useful cancer vaccine adjuvants in their ability to stimulate antigen-presenting cells (APCs) and subsequently amplify
the cytotoxic T-cell response. The purpose of this study was to characterize APC responses to
TLR activation and to determine the subsequent effect on lymphocyte activation. We exposed
murine primary bone marrow-derived macrophages to increasing concentrations of agonists to
TLRs 2, 3, 4, and 9. This resulted in a dose-dependent increase in production of not only tumor
necrosis factor–alpha (TNF-α), a surrogate marker of the proinflammatory response, but also
interleukin 10 (IL-10), a well-described inhibitory cytokine. Importantly, IL-10 secretion was not
induced by low concentrations of TLR agonists that readily produced TNF-α. We subsequently
stimulated lymphocytes with anti-CD3 antibody in the presence of media from macrophages
activated with higher doses of TLR agonists and observed suppression of interferon gamma
release. Use of both IL-10 knockout macrophages and IL-10 small-interfering RNA (siRNA)
ablated this suppressive effect. Finally, IL-10 siRNA was successfully used to suppress CpGinduced IL-10 production in vivo. We conclude that TLR-mediated APC stimulation can induce
a paradoxical inhibitory effect on T-cell activation mediated by IL-10.
Keywords: toll-like receptors, innate immunity, IL-10

Introduction
Immunotherapy remains an exciting, yet largely unfulfilled, modality in the treatment
of malignant disease. Myriad treatment strategies have been explored, including vaccination against viral precursors, cytokine manipulation, adoptive T-cell transfer, and
dendritic cell administration.1 Obvious theoretical potential and astonishing anecdotal
successes continue to fuel investigation.
The development of tumor-specific vaccines for either adjuvant or neoadjuvant
therapy represents an extremely attractive approach; however, the challenges associated
with their development have been starkly illustrated as the intricacies of the so-called
“escape” phase of cancer immunoediting have been elucidated. These include loss
of antigen-presenting machinery, decreased expression of tumor antigens, reduced
sensitivity to immune effector molecules, expression of inhibitory molecules, and
induction of regulatory cells including regulatory T-cells (Tregs).1
Stimulation of Toll-like receptors (TLRs), components of the innate immune system, are extensively studied as a means for overcoming tumor escape mechanisms.
TLRs are the best-characterized class of pattern recognition receptors in mammalian
species,2 detecting unique nonself-molecular patterns conserved throughout entire
classes of pathogens.3 The reasoning behind their use as anticancer agents is twofold.
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First, activation of the innate immune system and subsequent
production of an appropriate cytokine and chemokine milieu
will promote a direct cytotoxic antitumor response.4 Second,
their activation also augments the development of adaptive
responses that can be exploited to accelerate vaccines for
tumor-specific immunity.5
There are likely between 10–15 unique TLRs in
mammalian species.2 At least 11 TLRs are identified in
humans, and these are well conserved in mouse species.6
TLRs recognize multiple pathogen-associated molecular
patterns, including bacterial lipoproteins (TLR2); doublestranded RNA (TLR3); lipopolysaccharide (LPS) (TLR4);
flagellin (TLR5); single-stranded viral RNA (TLR7); and
unmethylated CpG DNA (TLR9), that are unique to bacteria
and viruses.
In order to augment the development of a cancer vaccine,
our laboratory has explored the use of TLR agonists as vaccine adjuvants. In so doing, we sought to examine the murine
APC cytokine response to TLR activation and the subsequent
effect of this activation on lymphocytes. Here, we identify a
dose-response curve of cytokine production in bone marrowderived macrophages (BMM) after the activation of TLRs
2, 3, 4, and 9. This cytokine production is characterized by
increasing levels of not only the proinflammatory cytokine
tumor necrosis factor–alpha (TNF-α), but also the inhibitory
cytokine interleukin 10 (IL-10) that inhibited lymphocyte
activation in vitro. Finally, we show that this inhibitory effect
can be overcome by targeting IL-10 with small-interfering
RNA (siRNA) both in vitro and in vivo.

Materials and methods
Mice
Female A/J, C57BL/6, and IL-10 deficient (C57BL/6 background) mice were purchased at 4 weeks of age from The
Jackson Laboratory (Bar Harbor, ME). After arrival, mice
were acclimated for at least 4 days prior to use. Animals
were housed in specific pathogen-free conditions in the
Animal Laboratory at Children’s National Medical Center.
All mice were handled in accordance with the guidelines of
the Institutional Animal Care and Use Committee.

Reagents
OK-432 was obtained from Chugai Pharmaceutical Co
(Tokyo, Japan). CpG-ODN 1826 was purchased from Coley
Pharmaceutical Group (Wellesley, MA; Lot# C44-0604AE1A). Polyinosinic:polycytidylic acid sodium salt (Poly
I:C) was purchased from Sigma-Aldrich (St Louis, MO;
Product #PO913).
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Macrophage harvest and growth
Primary bone marrow macrophages were directly harvested
from sacrificed A/J and C57BL/6 mice. Femurs and tibias
were dissected and the intramedullary canals were flushed
with PD solution (phosphate-buffered saline containing 1%
penicillin–streptomycin) via a 26 g needle until the bones
were clear. Cells were resuspended in PD solution and
centrifuged. The cells were then cultured in canted neck flasks
(CellStar 658190 T75 Flask, Greiner Bio-One, Monroe, NC;
suspension culture, sterile, plug seal cap, 250 mL) containing
30% L929 cell-conditioned media in a humidified incubator
at 37°C with 5% CO2. Cells were refed on either day 2 or 3,
then plated between days 6 and 9 into 24-well plates. 2 × 105
cells were plated in each well with 350 µL of D10 solution
(Dulbecco’s modified Eagle’s medium [DMEM], supplemented with 10% fetal bovine serum [FBS], penicillin [100
IU/mL], streptomycin [100 µg/mL] [all Sigma-Aldrich],
and 1% L-glutamine [Mediatech Inc, Manassas, VA]). The
24-well plates were then returned to the incubator and macrophages were given at least 16 hours to acclimate prior to
stimulation. The obtained cell population was 99.6% positive
for CD11b, 88.7% for F4/80, 83.9% for CD14, 30.2% for
CD11c, and ,1% for Gr1 (data not shown).

Flow cytometry
Cultured bone marrow cells were collected and stained with
the following fluorochrome-conjugated murine antibodies (mAbs) obtained from eBioscience (San Diego, CA):
phycoerythrin:cyanine-5 (PE-Cy5)-conjugated CD11b
(M1/70), allophycocyanin (APC)-conjugated CD11c (N418),
phycoerythrin (PE)-conjugated F4/80 (BM8), fluorescein
isothiocyanate (FITC)-conjugated CD14 (Sa2-8), and
allophycocyanin (APC)-conjugated Gr1 (RB6-8C5). Flow
cytometry was performed using FACS Calibur (BDBioscience, San Jose, CA); results were analyzed using FlowJo
software (Treestar, Ashland, OR).

Macrophage stimulation
At the conclusion of the acclimation period, varying amounts of
CpG, Poly I:C, and OK-432 were administered to the cells. The
macrophages were then reincubated for 24 hours before either
cytokine assay or splenocyte stimulation was performed.

Splenocyte harvest
Spleens of sacrificed A/J and C57BL/6 mice were removed
and crushed through cell strainers (BD Biosciences, San Jose,
CA). Strained cells were then centrifuged and re-suspended in
R10 Solution (RPMI media containing 10% FBS, penicillin
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[100 IU/mL], streptomycin [100 µg/mL], 1% L-glutamine,
25 nM HEPES buffer [Mediatech Inc], and 0.005 mM
B-mercaptoethanol [Sigma-Aldrich]). A cell-count was
performed using trypan blue to ensure cell viability. 2 × 105
cells per well were plated into 96-well round-bottom plates;
each well contained 150 µL of RPMI solution.

Splenocyte stimulation

Immediately after the splenocytes were plated, 150 µL of
stimulated macrophage supernatant was added to each well in
combination with 1.0 µg/mL of purified anti-CD3 (BD Biosciences; Cat # 553058, αCD3e) for lymphocyte activation.
Splenocytes were then incubated at 37°C for 48 hours prior
to cytokine assay.

siRNA oligonucleotide design
and validation
All RNA oligonucleotides used in this study were synthesized
and high-pressure liquid chromatography (HPLC)-purified by
Integrated DNA Technologies (Coralville, IA). Compound
identity was verified by electrospray ionization mass spectrometry (ESI-MS) and compound purity was measured to
be better than 90% by analytical HPLC. Final duplexes were
prepared in sodium salt form. Ten Dicer-substrate siRNAs
(DsiRNAs)7,8 targeting murine IL-10 (NM_010548) were
tested for functional potency as described below. The most
potent DsiRNA (mIL10-1) was an asymmetric duplex with
a 25-base passenger strand and a 27-base guide strand with
sequence 5′-pGGAUCUUAGCUACGGAAACAACtc-3′
(S-strand) and 5′-pGAGUUGUUUCCGUUAGCUAAGAU
CCCU-3′, where RNA bases are uppercase, DNA bases are
lowercase, and p is phosphate. For all experiments, the negative control DsiRNA NC1 was employed with sequence 5′-p
CGUUAAUCGCGUAUAAUACGCGUat-3′ (S-strand) and
5’-pAUACGCGUAUUAUACGCGAUUAACGAC-3’ (ASstrand) and for some experiments the positive control antiHPRT1 (NM_000194) DsiRNA was employed with sequence
5′-pGCCAGACUUUGUUGGAUUUGAAAtt-3′ (S-strand)
and pAAUUUCAAAUCCAACAAAGUCUGGCUU (ASstrand). The anti-HPRT1 DsiRNA works as a positive control
for human, mouse, and rat cells lines equally well.
The murine macrophage cell line RAW 264.7 was
employed for all DsiRNA validation experiments (ATCC,
Manassas, VA; Cat #TIB-71). Cells were split into 48-well
plates at 60% confluency (250,000 cells per well) at the
time of transfection in 250 µL DMEM containing 10% FBS
(ATCC). RNA duplexes were transfected at 10 nM, 1 nM,
and 0.1 nM final concentrations with 2.5 µL TransIT-TKO®
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(Mirus, Madison, WI) per 50 µL OptiMEM™ I (Invitrogen,
Carlsbad, CA). The HPRT1 DsiRNA was used as an internal
positive control to assess transfection efficiency and the NC1
DsiRNA was a nontargeting negative control. All transfections
were performed in triplicate. Twenty-four hours post-transfection, all transfected wells were stimulated with 50 ng/mL
Escherichia coli K12 LPS (InvivoGen, San Diego, California)
for 8 hours to induce IL-10 production. RNA was harvested
32 hours post-transfection using the SV96 Total RNA Isolation
Kit (Promega, Madison, WI) and cDNA was synthesized using
150 ng total RNA with SuperScript™-II Reverse Transcriptase
(Invitrogen) per the manufacturer’s instructions using both
random hexamer and oligo-dT priming.
Quantitative real-time polymerase chain reaction (PCR)
was performed using 10 ng cDNA per 10 µL reaction, Immolase™ DNA Polymerase (Bioline, Randolph, MA), 200 nM
primers, and 200 nM probe. IL-10 specific primers were
IL-10-For 5′-GTACAGCCGGGAAGACAATAAC, IL-10Rev 5′-TTGGCAACCCAAGTAACCC, and probe IL-10-P
5′ FAM-TGCCTTCAGCCAGGTGAAGACTTT-IBFQ
(Iowa Black FQ, dark quencher). HPRT1-specific primers
were HPRT-For 5′-GACTTTGCTTTCCTTGGTCAGGCA,
HPRT-Rev 5′-GGCTTATATCCAACACTTCGTGGG
and probe HPRT-P 5 ′-MAXN-ATGGTCAAGGT
CGCAAGCTTGCTGGT-IBFQ. Cycling conditions
employed were: 95°C for 10 minutes followed by 40 cycles of
two-step PCR with 95°C for 15 seconds and 60°C for 1 minute.
PCR and fluorescence measurements were done using an ABI
Prism™ 7900 Sequence Detector (Applied Biosystems Inc,
Foster City, CA). All reactions were performed in triplicate.
Expression data were normalized to levels of an internal
control gene, RPL23 (NM_022891). RPL23 specific primers were RPL23-For 5′ CTGTGAAGGGAATCAAGGGA,
RPL23-Rev 5′ TGTCGAATTACCACTGCTGG, and
probe RPL23-P 5′ FAM-CTGAACAGACTTCCTGCTGC
TGGTG-IBFQ. Copy number standards were run in parallel
using linearized cloned amplicons for qualitative PCR assays.
Unknowns were extrapolated against standards to establish
absolute quantitative measurements.

siRNA transfection
Primary bone marrow macrophages were harvested as described
above. Cells were plated into 24-well plates and allowed to
acclimate for 16–24 hours. Lipofectamine 2000 (Invitrogen)
was combined with siRNA as directed by the manufacturer’s
guidelines. The final concentration of siRNA added to the cells
was 33 nM. Cells were incubated in serum-free transfection
medium for 8 hours, at which time the supernatants were
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removed and replaced with growth media. The cells were
stimulated after 16–24 hours of reacclimation.
To test targeting of cytokine response in vivo, we targeted
IL-10 by delivering IL-10 siRNA loaded into poly(lactic-coglycolic acid) (PLGA) microparticles (MPs) (Division of
Pharmaceutics, University of Iowa, Iowa City IA). Nonspecific siRNA (DsiRNA NC1) and empty PLGA MPs were used
as controls. A/J mice (four per group) received intraperitoneal
administration of siRNA in PLGA MPs (2.5 µg per mouse
suspended in 100 µL of phosphate-buffered solution). No
signs of distress were observed in any of the groups.
Peritoneal exudates were collected at 6, 12, and 18 hours
after PLGA injection. Peritoneal exudates were centrifuged
and cell pellets suspended and cultured overnight at 37°C in
DMEM with 10% serum (D10). After incubation, the supernatant was discarded and adherent cells were placed in triplicate
in 24-well plates with 250 µL of D10 media and allowed to
attach for 6 hours. Cells were then stimulated with 1 µg/mL
CpG. After 12 hours of stimulation, supernatants were recovered and analyzed by enzyme-linked immunosorbent assay
(ELISA) for their IL-10 and TNF-α concentrations.

Enzyme-linked immunosorbent assay
Cell culture supernatants were collected from triplicate wells
after stimulation. TNF-α and IL-10 secreted by BMM and
peritoneal macrophages, and interferon-gamma (IFN-γ)
secreted by lymphocytes were measured by ELISA using

Cytokine (pg/mL)

Experiments were performed in triplicates. Error bars indicate
standard error of the mean (SEM). Results are representative of
three independent experiments. For reverse transcription-PCR
experiments, error bars represent SEM for the triplicate quantitative PCR reactions performed on three biological replicates.
The statistical significance was evaluated using Student’s t-test.

Results
TLR agonists stimulate bone marrow
macrophages in a dose-dependent fashion
To characterize the responses to TLR stimulation, primary
BMM were exposed to varying concentrations of specific
TLR compounds and IL-12, TNF-α and IL-10 responses were
measured. We anticipated identifying an optimal TLR agonist
and dosage; however, irrespective of the TLR agonist used, the
BMM response was characterized by increasing production and
eventual plateau of the cytokine measured. In all TLRs tested,
production of IL-10 characteristically lagged behind that of
TNF-α (Figure 1) or IL-12 (data not shown) and only emerged
at higher concentrations of TLR-agonist. This indicates that
B
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Figure 1 Macrophage TNF-α and IL-10 production after exposure to varying concentrations of TLR agonists. Primary bone marrow macrophages were harvested from A/J mice,
plated, and stimulated with Poly I:C, a TLR3 agonist (A), CpG, a TLR9 agonist (B), OK 432, a TLR2/4 agonist (C), or various combinations of two agonists, as indicated. Cytokine levels
were measured by ELISA 16–24 hours after stimulation and expressed as pg/mL (A–C) or TNF-α/IL-10 ratios (D, mean and standard deviation of three separate experiments).
Notes: The differences between untreated and treated cultures are statistically significant (**P , 0.01; ***P , 0.001).
Abbreviations: TLR, Toll like receptor; TNF, Tumor Necrosis Factor; IL-10, Interleukin 10; ELISA, Enzyme linked Immunosorbent Assay; Poly I:C, Polyinosinic:polycytidylic
acid; CpG, Cytosine-phosphate-Guanin.
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response to TLR agonist could occur. Therefore, we developed an in vitro model to investigate the effect on lymphocyte
activation. Primary murine BMM were first exposed to TLR
agonists. After exposure, the activated macrophage supernatant
was collected and transferred to a culture of autologous murine
splenocytes stimulated with anti-CD3 antibody. Lymphocyte
activation was determined by IFN-γ production. Remarkably,
exposure of autologous splenocytes to the cytokine milieu of
TLR-activated macrophages consistently led to lymphocyte
suppression in comparison with controls exposed to anti-CD3
antibody alone (Figure 2A). Profound suppression of T cell
activation was achieved even with supernatants with cultures
containing relatively lower levels of IL-10 (eg, supernatants
from OK-432-stimulated macrophages). Importantly, IFN-γ
production was induced only by anti-CD3, and not by any agent
transferred from the primary culture (Figure 2B).

an optimal proinflammatory dose of each TLR-agonist can
be identified to maximize the production of TNF-α prior to
induction of IL-10 secretion. Importantly, secretion of IL-10
reaches maximal values at the same or slightly higher TLR
agonist concentrations relative to those that induce maximal
TNF-α production. Furthermore, no combination of two TLR
agonists was capable of selectively stimulating proinflammatory responses, as evident from the ratios of TNF-α and IL-10
production (Figure 1D). These observations suggest that in vivo
TLR agonist administration may be impractical if the goal is to
obtain a predominantly proinflammatory response.

Macrophage IL-10 production inhibits
in vitro lymphocyte activation
Given significant IL-10 production at higher doses of TLR
agonists, we hypothesized that a paradoxical anti-inflammatory
A
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Figure 2 Modulation of anti-CD3-induced IFN-γ production by TLR-stimulated macrophage supernatants. Whole A/J (A) or C57BL/6 (B) spleen cells were plated in the
presence of 1.0 µg/mL of anti-CD3 antibody.
Notes: The activation was performed in the presence of 100% supernatants of macrophages stimulated with OK-432 (10 µg/mL), CpG (3 µg/mL), LPS (10 µg/mL), or Poly I:C
(50 µg/mL), as indicated. Concentrations of combination of OK-432 and Poly I:C were also 10 µg/mL and 50 µg/mL, respectively. Not applicable (NA) represents splenocytes
plated with anti-CD3 antibody alone in the absence of any macrophage supernatant. Cytokine levels were measured by ELISA 48 hours after stimulation. The differences
between cultures containing supernatants from untreated and treated macrophages are statistically significant (***P , 0.001).
Abbreviations: TLR, Toll like receptor; TNF, Tumor Necrosis Factor; IL-10, Interleukin 10; ELISA, Enzyme linked Immunosorbent Assay; Poly I:C, Polyinosinic:polycytidylic
acid; CpG, Cytosine-phosphate-Guanin; LPS, Lipopolysaccharide; IFN, Interferon.
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To evaluate the role of IL-10 in this suppressive lymphocyte response, the experiment was repeated using BMM from
IL-10-knockout mice. Supernatants from TLR stimulated
IL-10 KO BMM did not inhibit IFN-γ production from
autologous splenocytes stimulated with anti-CD3 antibody
(Figure 3). These observations suggest that IL-10 is a critical
cytokine inhibiting lymphocyte activation in this model.

IL-10 siRNA targeting in macrophages
reversed the suppression of lymphocyte
activation induced by TLR-stimulated
macrophage supernatants
To directly and selectively target IL-10 production, we
investigated the use of IL-10 siRNA to suppress macrophage
IL-10 production. siRNA constructs were designed and subsequently tested for their ability to suppress IL-10 secretion
from a RAW macrophage cell line by quantitative reverse
transcription-PCR. IL-10 mRNA knockdown by the most
effective construct is shown in Figure 4. Lipofectamine 2000
was used to transfect BMM with this IL-10 siRNA construct.
Subsequent CpG-mediated activation of transfected BMM led
to a notable decrease in secreted levels of IL-10 (Figure 5A)
with minimal effect on TNF-α production (Figure 5B).
After demonstrating that BMM IL-10 production could be
constrained through the administration of IL-10 siRNA, we
applied this finding to the in vitro model of macrophage-mediated
lymphocyte activation described above. Supernatant from the

siRNA lipofected and stimulated macrophages was exposed
to autologous splenocytes in the presence of R10 media and
anti-CD3 antibody. Subsequent lymphocyte activation was
measured via IFN-γ ELISA. As seen in Figure 5C, lymphocytes exposed to IL-10 siRNA lipofected macrophage supernatant demonstrated an approximately fourfold increase in
IFN-γ activity. These findings show that suppression of IL-10
following macrophage TLR stimulation induces a cytokine
milieu conducive to T-cell activation.

IL-10 production is suppressed in vivo
following treatment with IL-10 siRNAloaded PLGA microparticles
PLGA MPs loaded with IL-10 or control siRNA were
injected intraperitoneally at a dose of 2.5 µg per mouse and
peritoneal exudate was harvested 6 hours later. This time
point was chosen because after 6 hours of in vitro exposure,
more than 90% of peritoneal exudate cells engulfed PLGA
MPs (Figure 6) and longer incubations were associated with
concomitant nonspecific effects (data not shown). CpG
stimulation (1 µg/mL) of peritoneal exudate cells resulted in
significantly reduced IL-10 levels following treatment with
IL-10 siRNA-loaded PLGA-MPs, while TNF-α levels were
not affected (Figure 7A). Furthermore, IFN-γ response following T lymphocyte activation was higher when stimulated
in the presence of supernatants of in vivo IL-10 siRNAloaded macrophages (Figure 7B).
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Figure 3 Modulation of anti-CD3-induced IFN-γ production by supernatants of TLR-stimulated IL-10-deficient macrophages.
Notes: Methods and TLR agonist concentrations are identical to those listed in Figure 2. Macrophage control represents supernatant from unstimulated macrophages
in combination with splenocytes and anti-CD3. Splenocyte control represents splenocytes incubated in the presence of anti-CD3 without macrophage supernatant. The
differences between cultures containing supernatants from untreated and treated macrophages are statistically significant (**P , 0.01; ***P , 0.001).
Abbreviations: TLR, Toll like receptor; IL-10, Interleukin 10; CpG, Cytosine-phosphate-Guanin; LPS, Lipopolysaccharide; IFN, Interferon.
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Notes: At 24 hours, cells were stimulated with 50 ng/mL LPS and RNA was
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Discussion
Our findings demonstrate the paradoxical anti-inflammatory
response of murine BMM to TLR stimulation. This effect is
mediated by IL-10 production, a well-described suppressor of
immune responses. IL-10’s suppressive effects are mediated
through a variety of mechanisms; including downregulation
of macrophage and dendritic cell antigen-presenting capacity,
blocking secretion of cytokines and chemokines, preventing
expression of costimulatory molecules and chemokine receptors, increasing generation of free-radicals and upregulating
expression of β2-integrin ligand (intracellular adhesion
molecule 1).9 In addition, the current work shows that IL-10
produced by macrophage stimulation is responsible for suppressing T-cell activation. In direct contrast, the production of
proinflammatory cytokines, such as TNF-α drive the polarization of CD4+ T-cells towards a Th-1 phenotype. Thus, the
pro- vs anti-inflammatory cytokine balance is crucial in the
control of immune homeostasis,10 and their relative expression in response to TLR stimulation has implications for
the clinical application of TLR agonists to cancer treatment,
including their use as cancer vaccine adjuvants.
Recent evidence supports the concept of a paradoxical
anti-inflammatory response to TLR stimulation. Murine bone
marrow dendritic cells stimulated with TLR 2 (Pam3CSK4)
and TLR 4 (LPS) agonists demonstrate a dose-dependent
increase in IL-10 secretion.10 Moreover, high-dose CpG
induces CD19+ dendritic cell-mediated activation of suppressor T-cells via an indoleamine 2,3-dioxygenase (IDO)
pathway, a response that is particularly prominent in areas

ImmunoTargets and Therapy 2012:1

of chronic inflammation and resultant constitutive IDO
expression, such as the tumor microenviornment.11,12 Taken
together, these findings highlight the variability of the immunologic response to TLR agonists, ostensibly as mechanisms
to allow the avoidance of unregulated local inflammation.
Unfortunately, they add additional layers of intricacy to the
use of TLR agonists as vaccine adjuvants. Our finding that the
transition from pro- to anti-inflammatory cytokine secretion
occurs following relatively small increases of TLR agonist
concentration additionally complicates their use. Beyond
optimizing the target microenvironment for TLR agonist
administration, simple variation in individual pharmacokinetics could make accurate adjuvant dosing challenging.
Dendritic cells are the most important antigen presenting
cell type in promoting immune responses.13,14 Just like macrophages, dendritic cells produce IL-10 in response to TLR
stimulation.10 In fact, inhibition of IL-10 production by dendritic
cells is one of the many strategies being attempted with the
hope of successful immunotherapy of tumors.15 However, IL-10
is produced by and affects the function of many cell types,16
and the ultimate fate of immune response induction does not
rest solely on dendritic cells. In fact, the immunosuppressive
potential of macrophages and myeloid-derived suppressor
cells is well known.17 Hence, targeting of IL-10 production
as part of raising anti-tumor immunity should be inclusive
of as many cell types as possible. Our siRNA approach is
designed to efficiently target cells with antigen-processing
abilities, which includes both dendritic cells and macrophages.
By constraining macrophage TLR-mediated IL-10 production through administration of siRNA and, consequently,
augmenting activated splenocyte IFN-γ production, we have
demonstrated an ability to augment the efficacy of TLRagonists in vitro. In order for this finding to have clinical
utility, in vivo IL-10 modulation will be necessary. Several
potential strategies exist in which investigators have explored
the use of anti-IL-10 antibodies; one in particular has demonstrated its efficacy in humans in the treatment of systemic
lupus erythematosus.18 The “paradoxically beneficial” effect
of anti-IL-10 is due to an effect of IL-10 on B cells helping
produce (auto)antibodies in lupus. The use of IL-10 signaling
pathway inhibitors are also shown to have in vitro efficacy, as
demonstrated in the above-mentioned study by Hirata et al,
where inhibitors of the p38 mitogen-activated protein kinase
(MAPK), and c-jun N-terminal kinase (JNK)1/2 pathways
effectively constrained IL-10 production.10 Finally, a recent
study utilized JC virus-like particles for the targeted delivery of IL-10 siRNA in mice.19 While the first of these three
options has been the most extensively studied, the last two
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Figure 5 IL-10 siRNA decreases IL-10 production and abolishes suppression in vitro. A/J macrophages were transfected with IL-10 siRNA using Lipofectamine 2000 reagent
and stimulated with 1.0 µg/mL CpG. Shown are levels of IL-10 (A), or TNF-α and IL-10 in primary overnight cultures (B), or levels of anti-CD3-induced IFN-γ production
by spleen cells in the presence of primary culture supernatants (C).
Notes: The differences between Lipofectamine 2000-treated and IL-10 siRNA-treated cultures are statistically significant for IL-10, but not TNF-α production (*P , 0.05;
***P , 0.001).
Abbreviations: TNF, Tumor Necrosis Factor; IL-10, Interleukin 10; CpG, Cytosine-phosphate-Guanin; IFN, Interferon; HPRT, Hypoxantine-guanine phosphorybosyltransferase.

20

submit your manuscript | www.dovepress.com

Dovepress

ImmunoTargets and Therapy 2012:1

Dovepress

Toll-like receptor activation of macrophages

A

200 µm

200 µm

200 µm

200 µm

200 µm

No PLGA

PLGA 1 hour

PLGA 2 hour

PLGA 6 hour

PLGA 12 hour

B

100
80
% cells

C

60
40
20
0
1h

2h

4h

6h

12 h

Macrophage PLGA MPs uptake per cell
50

Number of PLGA MPs

PLGA MPs uptake by peritoneal
macrophages

40
30
20
10
0
1h

2h

4h

6h

12 h

24 h

Figure 6 Uptake of PLGA MPs in vivo. A/J mice were injected with PLGA MPs and peritoneal exudate cells were examined at indicated time intervals (1, 2, 6 and 12 hours
post injection) by light microscopy. Shown are representative images for each time point (A), percentage of cells loaded with PLGA MPs (B) and average number of PLGA
MPs per cell (C).
Abbreviation: PLGA MPs, Poly lactic-co-glycolic acid microparticles.

may prove to be more effective, as TNF-α and IL-10 secretion can exhibit a synergistic relationship in which the
presence of the former amplifies secretion of the latter.20 As
demonstrated by our data, the converse does not seem to be
true; moreover, previous studies on human monocytes have
demonstrated that IL-10 can in fact inhibit TNF-α secretion.21
De novo prevention of IL-10 production is therefore less
likely to prevent TNF-α secretion than post hoc ablation of
its effects.
Previous studies have both detected secretion of antiinflammatory cytokines and demonstrated techniques to
constrain their production. However, our study takes comparable findings a step further by developing an in-vitro
model to demonstrate their effects on T-cell activation.
The fact that TLR 9 in humans is expressed in B-cells
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and plasmacytoid dendritic cells,22 but not monocytes or
macrophages like in the mouse, appears to limit the impact
of our findings to the mouse. However, our findings were
not specific to TLR9 stimulation, but pertained to all TLR
receptors tested.
Additionally, we demonstrated that siRNA constructs
can be effectively delivered by PLGA MPs both in vitro and
in vivo. The clinical use of PLGA MPs as a drug-delivery
system is expanding as it is a biocompatible polymer without systemic toxicity.23 We demonstrated that the uptake
of PLGA MPs by peritoneal macrophages reached at least
90% at 6 hours and that the uptake continued beyond that
time point as indicated by the rising number of MPs per cell
(Figure 6). This load was not deleterious as no suppression
of cytokine production was observed after a 12- and 24-hour
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Figure 7 Inhibition of IL-10 production in vivo by siRNA. A/J mice were injected with empty, IL-10 siRNA-loaded, or control NC siRNA-loaded PLGA MPs. Peritoneal
exudate cells were isolated, stimulated with CpG and examined for production of TNF-α and IL-10 (A). Supernatants of these cultures were added to anti-CD3-stimulated
spleen cells and production of IFN-γ was assessed (B).
Note: The differences between empty PLGA-treated and IL-10 siRNA-treated cells are statistically significant (***P , 0.001).
Abbreviations: IL-10, Interleukin 10; CpG, Cytosine-phosphate-Guanin; PLGA, MPs-Poly lactic-co-glycolic acid microparticles; IFN, Interferon.

exposure to empty MPs (data not shown). Slow biodegradable
materials such as PLGA could improve the stability of siRNA
and promote a sustained and localized effect on the target
organ or tissue.24 Macrophages preferentially phagocytose
the MPs, thus making these PLGA polymers a useful vehicle
for targeting macrophage function. Our in vivo experiments
indicated that macrophage exposure to siRNA-loaded PLGA
MPs was effective in suppressing IL-10 production, an effect
that could potentially be used in vaccine formulations to
augment host immunity.
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In conclusion, our data demonstrates that the secretion of proinflammatory cytokines in response to TLR
activation is balanced by the anti-inflammatory effects of
IL-10 secretion in a dose-dependent fashion. The production
of IL-10 prevents the development of the cytotoxic T-cell
response in an in vitro model of TLR activation. Targeting
macrophage IL-10 production through the administration of
siRNA abolishes the suppressive T-cell effect. As this applies
to the development of cancer vaccines, strategies to either
constrain or ablate IL-10 and enhance the proinflammatory
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response may improve the efficacy of TLR agonists as vaccine
adjuvants. Finally, in vivo suppression of macrophage IL-10
was successfully accomplished by IL-10 siRNA-loaded
PLGA-MP. MPs loaded with siRNA appear to present a
potential method for targeting of IL-10 production. These
findings should have important implications for modulating
immunity with siRNA strategies.
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